Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 17/20 | 0.66 |
| ▸ | SELP | P16109 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2742900 | 0.95 | SELE (0.71) | SELESELP | |
| SCHEMBL15214250 | 0.94 | SELE (0.74) | SELESELP | |
| SCHEMBL9999657 | 0.94 | SELE (0.66) | SELESELP | |
| SCHEMBL12216748 | 0.90 | SELE (0.69) | SELESELP | |
| SCHEMBL9999662 | 0.89 | SELE (0.64) | SELESELP | |
| Rivipansel SCHEMBL2958742 | 0.89 | SELE (0.83) | SELESELP | |
| SCHEMBL13574211 | 0.88 | SELE (0.66) | SELESELP | |
| SCHEMBL15298773 | 0.88 | SELE (0.62) | SELESELP | |
| SCHEMBL12216730 | 0.88 | SELE (0.64) | SELE | |
| SCHEMBL14667722 | 0.87 | SELE (0.64) | SELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261070-A1 | ANTI-EPILEPTOGENIC AGENTS | GLYCOMIMETICS, INC. | 2013-10-03 | — | — | US | disclosed |
| US-8361975-B2 | Compounds and methods for treatment of sickle cell or complications associated therewith | GLYCOMIMETICS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120015898-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF SICKLE CELL DISEASE OR COMPLICATIONS ASSOCIATED THEREWITH | GLYCOMIMETICS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015898-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF SICKLE CELL DISEASE OR COMPLICATIONS ASSOCIATED THEREWITH | HBG1, HBG2, SORD | SELE 8/4885SELP 55/4885 |
| US-20130261070-A1 | ANTI-EPILEPTOGENIC AGENTS | GAP43, PYGB, NLN | SELE 1302/4885SELP 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.